Novartis AGNVSNYSE
Loading
Cost of Revenue Over TimeStable
Percentile Rank36
3Y CAGR+5.7%
5Y CAGR-2.0%
Studio
Year-over-Year Change

Direct costs attributable to producing goods sold

3Y CAGR
+5.7%/yr
vs -5.5%/yr prior
5Y CAGR
-2.0%/yr
Recent acceleration
Acceleration
+11.2pp
Accelerating
Percentile
P36
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
3 yr
Consecutive growthStable
PeriodValueYoY Change
2025$13.69B+6.7%
2024$12.83B+2.8%
2023$12.47B+7.7%
2022$11.58B-1.3%
2021$11.73B-22.4%
2020$15.12B+4.8%
2019$14.43B-0.6%
2018$14.51B+6.4%
2017$13.63B-22.2%
2016$17.52B-